February 23rd 2024
Results of a study conducted by the National Institutes of Health indicate that the Paxlovid prevented a substantial number of hospitalizations associated with COVID-19.
February 20th 2024
Planning for a post-recession scenario is essential, ensuring companies are prepared to scale up when funding permits.
February 12th 2024
The FDA granted accelerated approval to Elahere in November 2022 for adults with folate receptor-alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Entrenched and emerging hurdles alike are challenging manufacturer pricing and access strategies.
February 9th 2024
Key steps in relationship-building beyond just treatment options.
Assessing HCP-Visit Fallout: COVID’s Ultimate Impact on New Drug Entrants
Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.
Elevating ESG Message: Today’s Modern Investor is Key
How pharma companies can make sure their corporate strategy in ESG is appealing to younger generations—and aligns with the issues this large segment of sustainability investors care about most.
What Pharma Can Learn From the Consumer Market When It Comes to ESG
The pharma industry is beginning to perform better with environmental, social, and governance (ESG).
Pharma’s Training Transformation: COVID Forces Compliance Revamp, Re-education
How one company in particular has adjusted its internal and customer-facing strategies in compliance training amid today’s heightened business-risk climate.
The Potential of Proteomics
Major stakeholders—including policymakers, public-private interests, and academia—are increasingly embracing the potential of proteomics technology in reshaping diagnostics and patient care.
Embracing the Renaissance of Small Molecule Drug Discovery
Pharma companies may benefit from meeting challenges and embracing small molecule drug discovery.
Q&A with Dr. Kyle Flanigan, Ph.D., Co-Founder and CEO of USSF
Dr. Kyle Flanigan, Ph.D., discusses the benefits of an oral COVID-19 vaccine.
Q&A With ConnectiveRx CEO Jim Corrigan
Corrigan discusses the importance of a patient-centric approach.
Policy Reforms for Orphan Drugs
Outlook for orphan PRMA environment in the US, EU4, and UK.
It’s Time to Invest in Reproductive Medicine and Maternal Health
Amidst lack of funding for women’s health research, industry must collaborate now to advance RMMH.
Q&A With Chris Round, president, EMD Serono
Round discusses how he adjusted his leadership style and approach to patient care in the most effective way during the pandemic.
Q&A With Natalie DiMambro, vice president, product commercialization and training at Within3
DiMambro discusses how companies can update their systems and strategies to collect data which ensures that marginalized groups and diverse voices are included.
Q&A With Paul Ford, co-founder and president, DS9 Capital
Ford discusses how rising drug costs in impact patients, and how they can either avoid them or find less-expensive options.
Orphan Drugs: From Niche to Mainstream
Larger pipeline and increased support from regulatory authorities are setting up the orphan drug market for long-term success.
Why Are We Surrendering to COVID?
Industry must continue research and development to combat the pandemic.
Q&A With Matt Flesch, vice president of communications and patient advocacy, Horizon Therapeutics
Flesch speaks with Pharm Exec about his work to bring a patient-centric approach to the forefront of the industry.
A New Era in European Life Sciences Investment
Investments setting up sector for future success that could one day rival its US counterpart.
The Agile Future of Medical Information: Meeting 21st-Century Demands for Healthcare
COVID-19 pandemic has accelerated raised expectations for medical information professionals.
Q&A With Michael Moorman, principal at ZS Associates
Moorman discusses critical aspects of key account management in pharma.
IQVIA Releases Global Oncology Trend Report for 2022
While patients continue to benefit from increased product launches, the pandemic is still having an impact on caseload.
Q&A With Javier Szwarcberg, MD, MPH, CEO of Spruce Biosciences
Szwarcberg discusses challenges in the rare disease drug development space, and how his background is helping him find solutions for patients, specifically with endocrine disorders.
Partnering to Respond to a Possible Nuclear Threat
Recent explosion at Zaporizhzhia nuclear power plant in Ukraine shows how pharma industry can pull together and take action in the face of adversity.
Sustaining Pace With Contingent Workers
Pandemic workforce trends continue to create challenges for pharma.
Three Key Steps to Unlocking mRNA’s Potential Beyond COVID-19
Improvements in R&D, manufacturing, and data sharing will extend platform’s reach.
Aligning Contracting to Solve for Payer Risks Is a Win for Biopharma, Payers, and Patients
Upcoming regulatory changes to create new opportunity for specialized offerings.
What the COVID-19 Vaccine Process Showed Us, and How It Can Impact the Future of Drug Development
Industry has shown it can overcome challenges en route to creating new therapies.
Why Pharmaceutical Manufacturers Must Navigate Muddy Waters of ESG Requirements
Rise in demand for sustainable practices forces industry to be more proactive.
Q&A With Harvard Business School Professor Linda A. Hill
Hill shares her insights on what is needed for a turnaround in talent development.
If Content Is King, Context Is the Power Behind the Throne
New mediums of technology must be utilized correctly to reap full benefits.
Biopharma and ESG: Key Strategies for Companies, Meaningful Changes to Communities
New regulations set stage for updated ESG considerations.
2 Commerce Drive Cranbury, NJ 08512